Trial reportJournal of neuroimmunology2011
RTL therapy for multiple sclerosis: a Phase I clinical study.
Trial report in Journal of neuroimmunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05080270 (Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
Who cites it
32 citing papers in PubMed.
- Bridging Inflammation and Oncology: The Role and Therapeutic Potential of Macrophage Migration Inhibitory Factor in Lung Cancer.International journal of molecular sciences · 2026Review
- Cellular Immunotherapies for Multiple Sclerosis: Mechanistic Insights and Clinical Advances.International journal of molecular sciences · 2026Review
- MIF contribution to progressive brain diseases.Journal of neuroinflammation · 2024Review
- Hallmarks of Cancer Affected by the MIF Cytokine Family.Cancers · 2023Review
- Review of potential medical treatments for middle ear cholesteatoma.Cell communication and signaling : CCS · 2022Review
- Partial MHC/neuroantigen peptide constructs attenuate methamphetamine-seeking and brain chemokine (C-C motif) ligand 2 levels in rats.European journal of pharmacology · 2020Article
- Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis.Brain sciences · 2020Review
- Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.Expert opinion on therapeutic targets · 2019Review
- A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury.Journal of neuroinflammation · 2019Review
- Antigen-specific immunotherapies in rheumatic diseases.Nature reviews. Rheumatology · 2017Review
- Partial MHC class II constructs as novel immunomodulatory therapy for stroke.Neurochemistry international · 2017Review
- Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.Neurochemistry international · 2017Article
- MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics.Expert opinion on therapeutic targets · 2017Review
- Sex differences in the immune response to experimental stroke: Implications for translational research.Journal of neuroscience research · 2017Review
- Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion.Translational stroke research · 2016Article
- Emerging immunopharmacological targets in multiple sclerosis.Journal of the neurological sciences · 2015Review
- Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke.Translational stroke research · 2014Article
- Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy.Frontiers in cellular neuroscience · 2014Article
- Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects.European journal of immunology · 2013Article
- Effective Arrestin-Specific Immunotherapy of Experimental Autoimmune Uveitis with RTL: A Prospect for Treatment of Human Uveitis.Translational vision science & technology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A human recombinant T cell receptor ligand (RTL1000) consisting of DR2 α1 and β1 domains linked covalently to MOG-35-55 peptide can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), and was evaluated for safety in a Phase 1 randomized, placebo-controlled, escalating dose study in 34 subjects with multiple sclerosis (MS). RTL1000 was safe and well tolerated at a dose of ≤60 mg that is well within the effective dose range for EAE and did not cause worsening of MS disease at doses ≤200 mg. RTL1000 represents a novel approach for the treatment of MS that promises potent immunoregulation and CNS repair without global immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.